Driving Immune-Control of Solid Tumors

Revitope is developing a novel class of T cell engaging antibody circuits that redirect T cells to tumors with broad therapeutic applications in immuno-oncology.

Immune-based therapies are redefining how cancer is treated, as clinical studies demonstrate unprecedented deep and durable responses in multiple cancer types. In particular, redirecting T cells to tumors is a successful strategy for immunotherapy, but to date is limited by off-target toxicities and imperfect targets for solid tumors.

Revitope\'s engineered programmable antibody circuits are focusing immune activation to the cancer cell surface while expanding the antigenic targeting space on solid tumors to widen the therapeutic index in immuno-oncology.

Programmable Antibody Circuit Pipeline

Expanding the therapeutic window of T cell redirection therapies for solid tumors using Revitope\'s programmable antibody circuits has the potential to significantly improve the treatment outcome for millions of cancer patients.

Our focus is on solid tumors where:

There is substantial unmet medical need There are opportunities to capitalize on proprietary antigens for targeting There is a clear preclinical and clinical development path T Cell Engaging Antibody Circuit (TEAC) – Mechanism of Action Antibody Peptide Epitope Circuit (APEC) – Mechanism of Action Head of Biology / Immuno-Oncology

You are passionate about science, comfortable working in a highly results-oriented environment, and excited to bring innovative solutions to patients that help improve their lives. You should have a track record of identifying cancer/disease targets and assessing them in preclinical in vitro/in vivo models, as well as extensive expertise in preclinical models for IO. Additional experience in inflammation and autoimmune diseases is a plus. A solid understanding of the pathophysiology of cancer and translational experience in immuno-oncology is highly desirable. You should be an excellent manager, an effective team builder, and a strong collaborator.

(Senior) Scientist / Protein Biochemistry

We are looking for a highly motivated and enthusiastic Scientist/Senior Scientist to join our Protein Sciences team. You will be responsible for the design, production and characterization of proteins to help advance therapeutic candidates into the clinic and provide scientific expertise to the protein sciences group. This is an exciting opportunity to drive the development of the next-generation of T cell redirection biologics in a highly collegial environment.

Associate Scientist

We are now looking to add a highly motivated and enthusiastic Associate Scientist to our growing cross-functional team. This individual will perform cell-based and biochemical assays using a variety of molecular and immunological techniques. This is an exciting opportunity to contribute to the development of new biologics drugs for cancer immunotherapy in a highly collegial start-up biotech company and gain experience in all aspects of immuno-oncology drug discovery.

Revitope Oncology Appoints Steve Arkinstall, D.Phil., Chief Executive Officer

Cambridge, MA. | January 8, 2020 | PRNewswire | Revitope Oncology, Inc., a cancer therapeutics company advancing a novel class of tumor-specific bispecific antibody therapies, today announced the appointment of Steve Arkinstall, D.Phil., as Chief Executive Officer. Dr. Arkinstall brings more than 30 years of experience in biopharmaceutical research and development across multiple diseases areas, and is a respected industry leader.

Most recently, Dr. Arkinstall was CEO of Elstar Therapeutics, a venture-backed biotechnology company developing multi-functional antibody-based therapeutics to treat cancer. He previously was Chief Scientific Officer at Kymab, an antibody therapeutics company founded in Cambridge, UK, prior to which he spent 16 years in progressively senior research leadership roles at EMD Serono, and associated entities in Europe and the United States.

\"We are thrilled that a leader of Steve\'s caliber has chosen to join Revitope at this exciting time in the company\'s evolution,\" said Andrew Allen, M.D., Ph.D., Chair of the Revitope Oncology Board of Directors. \"Under the skilled direction of CSO and acting-CEO Werner Meier, the company has advanced its core T-cell engaging antibody circuit (TEAC) technology to successful in vivo studies. We must now select our first development candidates and advance into IND enabling studies as a prelude to clinical trials. Steve is a superlative, and experienced executive ideally equipped to lead us through these critical phases.\"

Revitope\'s TEAC technology consists of tumor-specific antibody circuits designed to focus immune activation to the cancer cell surface while expanding the antigenic targeting space on solid tumors, avoiding healthy tissues and widening the therapeutic index in immune-oncology.

\"A key challenge for immunotherapy for solid tumors in particular, has been the absence of antibody-accessible antigens on the surface of tumor cells which are suitably specific to the tumor,\" said Dr. Arkinstall. \"Revitope\'s \"AND\" gate technology, applied to antibody therapeutics, is an elegant and unique approach to the problem that offers a powerful solution. I am excited to be joining the team and look forward to driving this therapeutic approach forward to help cancer patients in a compelling new way. There is an abundance of targets to choose from and tremendous opportunity to leverage our technology through both in-house and partnered programs across cancer types.\"

Applied BioMath, LLC Announces Collaboration with Revitope for Mechanistic PK/PD Modeling in Solid Tumors

Concord, MA | July 10, 2018 | PRNewswire Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk and accelerate drug research and development, today announced a collaboration with Revitope for an in-vitro and human mechanistic PK/PD modeling of Revitope\'s bispecific T Cell Engaging Antibody Circuits (TEAC) targeting solid tumors. \"TEAC are designed to increase tumor specificity and launch an immune activation only when bound to the cancer cell surface. This innovative engineering approach has the potential to unleash potent immune responses that are focused entirely on the tumor,\" said Werner Meier, CSO and acting CEO of Revitope Oncology. \"Our goal in this collaboration is to leverage Applied BioMath\'s modeling and analyses capabilities to identify TEAC drug properties that drive the potential for a better therapeutic index and ideally more efficacy in immuno-oncology.\"

Applied BioMath employs a rigorous fit-for-purpose model development process, referred to as Model-Aided Drug Invention (MADI), which aims to quantitatively integrate knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their MADI approach employs proprietary algorithms and software that were designed specifically for mechanistic PK/PD modeling. \"Our mechanistic modeling approach allows our collaborators to assess the feasibility of their therapeutic much more quickly than if they were to rely on experiments alone,\" said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. \"They\'ll be able to quickly answer strategic questions about the ideal properties for their therapeutic concept and help accelerate development in Lead Generation and by prioritizing experiments, thus helping them get into the clinical faster and for less money with potentially a BIC therapeutic, giving themselves a much higher chance of clinical success and maximizing R&D ROI.\"

Servier backs American startup\'s research project at LabCentral

Paris, France Cambridge, US | April 26, 2018 | GLOBE NEWSWIRE Independent international pharmaceutical company Servier and LabCentral, a well-known launchpad for innovative startups in the United States, have announced that Revitope, a startup specializing in biotechnology, has won the Golden Ticket awarded by Servier as part of its sponsorship of the prestigious American coworking facility. The prize is a year\'s residency at LabCentral\'s facilities for a Revitope scientist. Located in Cambridge, LabCentral is at the heart of scientific and technological innovation in the United States.

Servier has been a Gold sponsor of LabCentral for two years. Each year, it can award a Golden Ticket to a startup in the field of healthcare in order to provide support for a research project corresponding to the Group\'s development strategy.

\"Servier is happy to have given this award to Revitope whose innovative technology could enable the therapeutic antibodies developed by the Group to precisely target the cells to be treated in patients with cancer and inflammatory diseases\", said Olivier Nosjean, Scientific Director of the Center of Excellence Research and Biopharmacy. \"In an open-innovation approach, Servier is committed to supporting promising startups in the field of healthcare, and particularly oncology, one of the company\'s priority areas of research.\"

The Golden Ticket award underwrites the cost of a lab bench for a Revitope scientist to reside in LabCentral\'s open lab for one year. This includes access to all the latest research equipment, shared infrastructure, extensive programming and services offered by LabCentral. The start-up will also benefit from LabCentral\'s corporate development support (co-working area, business coaching, investor relations).

\"A core principle in every aspect of what we do at LabCentral — from the design of our facilities and speaker series to our sponsorship programs and networking events — is a deliberate attempt to encourage interaction and collaboration,\" said LabCentral Cofounder and President Johannes Fruehauf, M.D., Ph.D. \"The Golden Ticket program is a great example. It\'s enormously gratifying to see our mission come to fruition, with Servier helping to support Revitope\'s continued work at LabCentral.\"

Revitope Oncology is developing prodrug platforms that have the potential to unleash potent immune responses that are focused entirely on the tumor. The company\'s programmable antibody circuits are designed to focus immune activation to the cancer cell surface while expanding the antigenic targeting space on solid tumors to widen the therapeutic index in immune-oncology.

Revitope Chief Scientific Officer Werner Meier, commented, \"We are very excited to have been selected by Servier as their Golden Ticket winner for 2017. It is particularly gratifying that an international pharma leader like Servier — laser-focused on bringing innovative therapies to patients across important therapeutic areas including cancer — is recognizing the potential of the Revitope prodrug platforms to widen the therapeutic index for T-cell redirection. The Servier Golden Ticket provides much-appreciated support that helps us to continue to be part of the LabCentral entrepreneur community — a terrific place for young, life sciences companies to grow.\"

The cooperation agreement with LabCentral is part of Servier\'s dynamic collaborative partnership strategy which aims to better respond to the challenges of therapeutic innovation by placing its research activities in the most dynamic research ecosystems where creativity, innovation and entrepreneurship are promoted and valued. This new agreement also confirms Servier\'s commitment to developing its partnership strategy in the United States.